MEMORANDUM RULING

PATRICIA MINALDI, District Judge.

Before the court are a Partial Motion for Summary Judgment from the plaintiff, Southwest Louisiana Hospital Association ("Hospital") [Doc. 40] filed on January 22, 2013, and a Motion for Summary Judgment from the defendant, BASF Construction Chemicals, LLC ("BASF") [Doc. 41], filed on January 22, 2013. BASF timely filed an opposition to the Hospital's motion [Doc. 44] as did the Hospital for BASF's motion [Doc. 46], on February 11, 2013. Both the Hospital [Doc. 50] and BASF [Doc. 52] and also filed replies for their respective motions on February 25, 2013. The Hospital filed a motion for hearing [Doc. 48], and the undersigned heard oral argument on the two motions on Tuesday, April 2, 2012 at 10:00 a.m. The court granted portions of both parties' motions,1 and took the remainder of the issues under advisement. For the foregoing reasons, the Hospital's Partial Motion for Summary Judgment is GRANTED and BASF's Motion for Summary Judgment is DENIED.

FACTUAL BACKGROUND

This case arises from the installation of a defective architectural wall system, referred to as Exterior Insulation Finish System ("EIFS") on the outer walls of the Hospital's Women & Children's Hospital facility ("facility") at the corner of Gauthier and Nelson Road in Lake Charles, Louisiana. The EIFS was manufactured by Finestone, but the defendant BASF is the successor-manufacturer for the product (via a merger on April 1, 2010), and thus appears as the named defendant in this case.2 The Hospital originally filed this action on April 29, 2010 in the Fourteenth Judicial Court of Calcasieu Parish, and BASF subsequently removed it to this court based on diversity jurisdiction soon thereafter.3

A. Construction of the Facility (2001-2003)

In 2000, the Hospital contracted with Bessette Development ("Bessette") to construct a three-building facility (containing a Utility building, Medical Office building, and Hospital building) at the corner of Nelson and Gauthier Roads in Lake Charles, Louisiana. Bessette, in turn, bid out portions of the building project to subcontractors. Eventually, Bessette selected Robbins Contracting ("Robbins")4 to construct the exterior walls of the facility. Robbins and one of the Hospital's architects, Michael Pomarico, then decided to use a Finestone Pebbletex EIFS product as the outer wall cladding system for the facility.5 In mid 2001, Pomarico and Bessette reviewed and approved "Finestone EIFS submittals" from Robbins, which contained, among other things, example warranty language, before acquiring the EIFS.6 At this point, Pomarico's main requirement for the EIFS was that it should have a ten-year warranty. Robbins subsequently purchased the EIFS materials from an EIFS supplier, F & W Architectural Products ("F & W") and began applying the EIFS to the facility in 2001, completing the project on or about January 14, 2003.

B. Discovery of Defect: "Weeping" Rust Stains in EIFS (December 2002)

Unfortunately, the EIFS finish coat contained iron pyrite particles that quickly began to rust, soon after the application of the EIFS to the buildings and before the construction of the facility was completed. On December 17, 2002, Robbins notified F & W of the rust appearing at the facility.7 In the meantime, on December 19, 2002, the Certificate of Substantial Completion was issued for the facility. In response to the rust, a complaint initiation form was then sent on December 30, 2002, noting "rust on the EIFS" and requesting a remedy to the problem.8 At the time the Hospital became aware of the problem and made a warranty claim, Finestone had not even issued a written warranty to the Hospital. Robbins then sent a January 14, 2003 fax to F & W, asking for the EIFS Warranty.9 The actual written EIFS warranty (a "Limited Warranty" for a term of ten years)10 was not delivered to the Hospital until April 28, 2003, but was dated January 14, 2003. This Limited Warranty waived implied warranties of merchantability and for fitness for a particular use, and limited the buyer's remedies to either replacement of the applicable coatings component or refund of the original purchase price.11

C. Remediation Efforts: First Pick and Clean (May 2003)

Robbins met with a Finestone representative on January 28, 2003 to discuss the rust issues with the EIFS. The representative's solution was a "pick and clean," in which a contractor would pick out the iron particles of the exterior wall using a knife, and then clean the rust stains with a solution. The Finestone representative then sent a follow up letter on February, 18, 2003, noting that the EIFS had exhibited "limited amounts of sand particles that cause[d] a slight color differential, and that Finestone would hire a contractor "at no cost to remove the affected particles."12 In May 2003, BASF hired a remediation contractor, Southern Stucco Coatings & Paint, to perform the "pick and clean" procedure. According to the Hospital, an internal Finestone memo noted that the rust could reappear and that Finestone should reinspect the site after six months, but Finestone did not conduct a follow-up inspection.13

D. Remediation Efforts: Second Pick and Clean (2005-2006)

About a month after the first remediation effort (June 2003), the Hospital once again noticed that the rust was reemerging, and they lodged another complaint with Finestone in December 2004. Finestone advised Robbins that it had recommended a second pick and clean effort to take place in the second quarter of 2005. Allegedly due to Hurricane Rita, Finestone delayed the second pick and clean until May 2006.14 Before the May 2006 pick and clean commenced, the Hospital contracted Robbins to remove and replace EIFS on the Utility building at the facility that had been damaged by Rita. In the course of performing work on the Utility Building, Robbins unilaterally decided to remediate the rust stains present on the building. While the Hospital alleges that Robbins performed the pick and clean procedure in accordance with Finestone protocol, BASF asserts that Robbins performed the work incorrectly (not using Finestone products), leading to "unique and distinct" rust stains on the Utility building. BASF has essentially disclaimed any responsibility for the Utility building in light of Robbins' work on it.15

E. Unsuccessful Meeting to Discuss Potential Third Pick and Clean (May 2008)

Finestone then had another contractor perform pick and clean remediation in May 2006 on the other two buildings at the facility (the Medical Office building and Hospital building). Following this second remediation, the Hospital once again noticed rust stains on the facility buildings and complained to Finestone. A Finestone representative (Mr. Bowen) met with Pomarico, Hospital representatives, a Bessette representative, and a Robbins representative to discuss the rust problem in May of 2008. Bowen once again recommended the pick and clean method. Pomarico refused, arguing that the only effective way to address the rust was to remove and replace the EIFS. The other Hospital parties agreed: the pick and clean appeared to be making things worse, not better.

F. Breakdown in Communication after Meeting (2008-2010)

After the May 2008 meeting, on or about June 2, 2008, Bowen transmitted a follow-up letter, memorializing in writing the offer to pick and clean the Hospital building and Medical Office building (but not the Utility building).16 Pomarico then sent a response letter to Finestone on August 5, 2008, requesting that Finestone to perform a limited, "sample" remediation procedure which the Hospital would then review to determine if a third pick and clean would be worth it (although he indicated in his deposition and in the letter that he thought it was very unlikely that the pick and clean would be a good long term solution).17 BASF alleges it never received this letter, and in the hearing, the parties noted that the person the letter was addressed to at Finestone no longer works there. After this August 2008 letter, it appears that the parties ceased communicating altogether.

Because Finestone allegedly never received Pomarico's letter, it closed the Hospital's file on August 19, 2009.18 The next year, on April 29, 2010, the Hospital filed this lawsuit.

MOTION FOR SUMMARY JUDGMENT STANDARD

A court should grant a motion for summary judgment when the pleadings, including the opposing party's affidavits, "show that there is no genuine issue as to any material fact and that the movant is entitled to judgment as a matter of law." Fed.R.Civ.P. 56(c); see also Celotex Corp. v. Catrett, 477 U.S. 317, 323-24, 106 S.Ct. 2548, 91 L.Ed.2d 265 (1986). The party moving for summary judgment is initially responsible for demonstrating the reasons justifying the motion for summary judgment by identifying portions of pleadings and discovery that show the lack of a genuine issue of material fact for trial. Tubacex, Inc. v. M/V Risan, 45 F.3d 951, 954 (5th Cir.1995). The court must deny the moving party's motion for summary judgment if the movant fails to meet this burden. Id.

If the movant satisfies this burden, however, the nonmoving party must "designate specific facts showing that there is a genuine issue for trial." Id. (quoting Celotex, 477 U.S. at 323, 106 S.Ct. 2548). In evaluating motions for summary judgment, the court must view all facts in the light most favorable to the nonmoving party. Matsushita Elec. Indus. Co. v. Zenith Radio Corp., 475 U.S. 574, 587, 106 S.Ct. 1348, 89 L.Ed.2d 538 (1986). There is no genuine issue for trial, and thus a grant of summary judgment is warranted, when the record as a whole "could not lead a rational finder of fact to find for the non-moving party ..." Id.

LAW AND ANALYSIS

I. The Hospital's Partial Motion for Summary Judgment

The Hospital makes two arguments in its motion: (1) that the remedy limitations and waivers of implied warranties in the Limited Warranty are unenforceable and (2) if the court finds that the Limited Warranty is enforceable, that ambiguity in the Limited Warranty should be construed in favor of the Hospital.

A. Enforceability of Remedy Limitations and Waiver of Implied Warranties in EIFS Limited Warranty

In its motion, the Hospital offers a three-part argument on whether the Limited Warranty's limitations of remedies (limiting the Hospital to either refund of the purchase price or replacement of the product) and waiver of implied warranties are enforceable.19 This argument forms the bulk of its Partial Motion for Summary Judgment.

1. Waiver of implied warranties and limitation of warranties in the EIFS warranty under the Prince test

The Hospital argues that the waiver of implied warranties and limitation of remedies within the Limited Warranty are unenforceable because: (1) they were not written in clear and unambiguous terms; (2) they were not contained in the sales documents; (3) they were not brought to the attention of the buyer and explained to them.

Before addressing the three elements required to effectively waive warranties, BASF makes an overarching argument that the Hospital is incorrectly conflating waiver of implied warranties supplied as a matter of Louisiana law (under La. Civ. Code Ann. art. 2520 and 2524) versus express warranties provided in the written EIFS warranty. Since the prescription period for the implied warranty claims (one year) has allegedly expired, BASF accuses the Hospital of attempting to avoid the consequences of prescription by arguing that the express EIFS Limited Warranty, which has a term of ten years, somehow incorporates implied warranties by failing to effectively waive them, thus meaning that the implied warranty claims are viable for a ten year period. Continuing, BASF notes that even if the Hospital is correct on this point, a breach of express warranty claim is still subject to a one year prescriptive period, regardless of the express warranty terms.

In its reply, the Hospital argues that BASF's argument on prescription of warranty claims is erroneous, for the reasons discussed infra in BASF's Motion for Summary Judgment. Turning to the waiver of implied warranties issue, the Hospital asserts that it is BASF who has ignored Louisiana jurisprudence in making its argument, and that Louisiana law "unquestionably requires" waiver to be clear and unambiguous, contained in the sales document, and brought to the Hospital's attention in order to be effective. Concluding, the Hospital asserts that while BASF correctly notes that this case involves implied warranty claims and express warranty claims, it erroneously accuses the Hospital of confusing the separate warranty obligations in an attempt to expand the terms of its written warranty. The Hospital notes that BASF issued the Hospital a warranty which guaranteed the EIFS would have certain aesthetic properties; instead, the Hospital got a "rust-riddled finish coat." As such, the Hospital alleges it is not trying to expand the terms of the warranty, but rather wishes to show that BASF's attempt to limit available damages, like its attempt to waive implied warranties, was ineffective.

The undersigned finds that BASF misconstrues the Hospital's argument in this section. The Hospital is simply stating that the waiver of implied remedies and the limitation of available remedies in the Limited Warranty were ineffective because BASF did not properly alert the Hospital about these waivers and limitations. It is not attempting to bootstrap the ten year warranty period onto implied warranty claims.

Turning to the relevant law, in 1973, the Louisiana Supreme Court, in Prince v. Paretti Pontiac Co., 281 So.2d 112 (La.1973), established than if a seller/manufacturer wishes to waive implied warranties, this waiver must be: (1) written in clear and unambiguous terms; (2) contained in the sales documents; and (3) brought to the attention of the buyer or explained to him. Id. at 117. Courts have deferentially applied this rule to consumer-purchasers, conforming to the Louisiana Supreme Court's finding that "safeguards protecting consumers must be more stringent than those protecting businessmen in the marketplace." Louisiana Nat'l Leasing Corp. v. ADF Serv., Inc., 377 So.2d 92, 96 (La.1979). Accordingly, waivers of implied warranties are often found ineffective, as they do not meet all three requirements of the Prince test. The seller/manufacturer has the burden of proving that the buyer waived the warranties. Pias v. Wiggins, (La.App. 3rd Cir.10/09/96), 688 So.2d 1103, 1106. Courts in Louisiana have also extended the three-part Prince test to warranty provisions which limit liability or recoverable damages. Harvey v. Mosaic Fertilizer, LLC, 2009 WL 3112144 (E.D.La.2009); Fontenot v. F. Hollier & Sons, 478 So.2d 1379 (La.App. 3 Cir.1985). Based on Louisiana jurisprudence, both the waivers of implied warranties and the limitations on remedies in the EIFS warranty must meet the above three requirements. Thus, the court will address each requirement in turn.

a. The warranty was written in clear and unambiguous terms

The Hospital first asserts that there are several terms in the EIFS Limited Warranty20 that are ambiguous: (1) it is unclear whether the waiver of implied warranties also waives claims for breach of implied warranty against redhibitory defects; (2) it is unclear what the waiver of "special, incidental, or consequential damages" means; and, (3) it is unclear whether "replacement" in the warranty means replacement of the EIFS wall or else simply delivering pails of new finish coat to the Hospital.

BASF counters that the implied warranty waivers are clear and unambiguous, and that the Hospital's assertion that terms like "replacement" are ambiguous is immaterial, as such terms are utilized in declaring the limited remedies under the express EIFS Limited Warranty, and not anything to do with the implied warranties.21 Citing to the relevant portion of the warranty that disclaims implied warranties, BASF asserts that it is clear that this language waives implied warranties.22

The Hospital replies that Louisiana law requires warranty limitations to be unambiguous so that a contract party can make an informed decision prior to accepting waiver of warranties. Since the Hospital did not even have the warranty when the rust appeared, it argues that the warranty was even worse than ambiguous: it was non-existent.

The Fifth Circuit case, Datamatic, Inc. v. International Business Machines Corp., 795 F.2d 458 (5th Cir.1986), provides guidance on whether this Limited Warranty language is clear enough in regards to the consequential damages provision and the waiver of implied warranties provision. In Datamatic, a manufacturer (IBM) sold computers to several corporations, including in the contract of sale a clause that expressly limited its liability as follows:

Id. at 460. The Fifth Circuit acknowledged that Louisiana law permitted a seller to limit or exclude the implied warranty against redhibitory defects, but that to be effective, the limitation or exclusion had to follow the requirements of the Prince test: (1) in the sales contract, (2) clear and unambiguous, and (3) brought to the buyer's attention. Id. at 464. While the court noted that usually, warranty limitations were construed against manufacturers, in the Datamatic case, "the IBM sales were to commercially sophisticated parties," allowing the court to hold the buyer to "a higher standard than an unknowledgeable customer." Id. at 465. The Fifth Circuit found that under this higher standard, the language was clear and unambiguous enough to allow for exclusion of implied warranties against redhibitory defects, and that the "consequential" damages provision was similarly clear and unambiguous. See id.

In this case, it cannot be said that a professional architect overseeing a large construction project would not be similarly considered a sophisticated party. Accordingly, the court will apply a higher standard than it normally would in a typical consumer case to discern whether the implied warranty waivers and consequential damages provisions are clear and unambiguous. Reading through the Limited Warranty, the waiver of implied warranties is similarly clear to the language in the Datamatic case: while it does not specifically mention waiver of implied warranties against redhibitory defects, it "makes no other warranty on FINESTONE COATINGS, including any implied warranty of merchantability or fitness for a particular use." Additionally, while the Hospital asserts that the warranty language limiting "consequential" damages ("FINESTONE shall not in any case be liable for special, incidental, or consequential damages") is too ambiguous to be enforceable, this language is also similar to the broad "consequential" damages language in the Datamatic case. The undersigned thus finds that these terms are both clear and unambiguous.

The clarity of the limitation on remedies (either replacement of the finish coat or refund of the purchase price) is more contentious.23 The Hospital argues that this limitation of remedies was ambiguous and unclear because "replacement" could mean replacement of the entire EIFS system or replacement of the defective finish coat only. It asserts that this was particularly important because replacement of only the finish coat would be worthless remedy, since the finish coat could not be removed and replaced without destroying the rest of the EIFS system. BASF counters that the Hospital's dissatisfaction with this limited remedy does not render the limited remedy unenforceable, and that any issues with the sufficiency of the warranty were due to the negligence of Pomarico, who approved this Limited Warranty language by reviewing and signing off on the EIFS "submittals" from Robbins. It argues that, viewing the Limited Warranty as a whole, it is clear that the "limited" remedy of replacement of the coatings component or refund of the purchase price can only refer to the EIFS finish coat itself, and not the entire EIFS system. Further, it argues that because it was only responsible for the sale of the EIFS, and not the installation of the EIFS, it would not make sense for the Limited Warranty supplied by BASF to offer to strip and reclad the facility with replacement EIFS.

The applicable warranty language is as follows: "FINESTONE's sole liability is expressly limited to either the replacement of the applicable FINESTONE coatings component or refund of the original purchase price." Thus, the inquiry becomes, what exactly constitutes the "applicable coatings component"? Louisiana's Civil Code provides that "[e]ach provision in a contract must be interpreted in light of the other provisions so that each is given the meaning suggested by the contract as a whole." La. Civ. Code Ann. art. 2050. The Limited Warranty begins with this statement: "FINESTONE warrants that the FINESTONE Architectural Wall System ("System": product or products and packaged components manufactured by FINESTONE and approved insulation boards) will perform satisfactorily under normal weather conditions for ten years from the date shown below." Thus, the warranty differentiates between the entire EIFS "System" and the various "components" which make up the "System." The "coatings component" would thus be a part of the group of "components" that make up the "System." While this language leads to an unfortunate result for the Hospital, in that replacement of the one defective "component" part would potentially not remedy the ultimate problem, the undersigned cannot say that, when reading the contract as a whole, replacement of the "applicable coatings component" is so ambiguous and unclear to render the provision unenforceable under Prince. Accordingly, the undersigned will turn to the second and third requirements of the Prince test.

b. Despite the fact that the Hospital, through Pomarico, had some notice of BASF's intent to limit remedies and waive implied warranties, there is no evidence that the waivers and limitations were brought to Pomarico's attention and explained to him

The Hospital next contends that because the Limited Warranty was not contained in the sales document or contract (since the Limited Warranty was issued after the EIFS was installed), the Limited Warranty limitations and waivers cannot be controlling on the parties. Additionally, the Hospital asserts that the warranty waivers and limitations are not controlling because, at no point did Finestone bring the warranty to the Hospital's attention, nor explain the warranty limitations or waivers at any time before the rust appeared.

BASF counters that the implied warranty waivers and were provided to, and approved by, Bessette and the architect, Pomarico in 2001, in connection with (and prior to) their approval of the EIFS product for the facility, via the submittals they reviewed. It argues that Pomarico not only saw very similar warranty language in the submittals, he also "signed off on these submittals by initialing them. It also notes that the Hospital did not buy the EIFS product directly from Finestone, and thus it is disingenuous to assert that the implied warranties are waived because they were not included in an act of sale. Instead, the submittals were approved by Pomarico (which BASF argues put the Hospital on notice of the implied warranty waivers, since he was acting on behalf of the Hospital as its agent) and Bessette, and following approval, the EIFS was purchased by the subcontractor (Robbins) and installed onto the facility buildings. BASF also argues that the Hospital's argument that the implied warranty waivers were not brought to its attention also fails: Pomarico had notice of the waivers of implied warranties, which were stated in all caps in the submittal documents.

The Hospital replies by reasserting that BASF has offered no evidence of sales documents or a contract which set forth or incorporated the written Limited Warranty. It acknowledges that while it was Finestone's "right" to issue the warranty after installation of the EIFS, this does not excuse Finestone from alerting the Hospital of the waiver of implied warranties. The Hospital also rejects BASF's argument that the implied warranty waivers were supplied to the Hospital in submittals to Bessette and Pomarico, which contain somewhat similar warranty language. Instead, the only thing that matters is whether the waivers appear in the sales contract. Preliminary documents submitted beforehand do not count. It argues that even if the submittals are considered sufficient notice documents for the waiver of implied warranties, they are too vague and ambiguous to show disclosure of warranty limitations. Additionally, it notes that several of the terms in the final EIFS Limited Warranty are nowhere to be found in the submittal documents.

In support of its argument that the submittals put the parties on sufficient notice that implied warranties would be waived and remedies would be limited, BASF cites to the Western District of Louisiana case, Hollybrook Cottonseed Processing, LLC v. Carver, Inc., No. 09-0750, 2010 WL 1416781 (W.D.La., April 1, 2010). BASF makes the general assertion that, when sophisticated parties are involved, waivers are enforceable as long as they are clear and unambiguous and the party has notice of them. Turning to Hollybrook case, however, the court construed Pennsylvania law, not Louisiana law, to ascertain whether the limitation of liability provisions in the contract were binding on the parties. See id. at *5. Further, the additional cases BASF cites for the proposition that sophisticated parties are held to a higher standard in instances where the other party tries to limit or waive remedies only addressed whether waiver terms in a limited warranty were ambiguous. See Datamatic, Inc. v. International Business Machines Corp., 613 F.Supp. 715, 720 (W.D.La.1985); Orthopedic & Sports Injury Clinic v. Wang Laboratories, Inc., 922 F.2d 220, 226 (5th Cir.1991). Indeed, in Datamatic, the limited warranty language actually appeared in the sales contract, and the buyer signed the sales contract. Datamatic, 613 F.Supp. at 720-21.

In contrast, the Hospital cites heavily to the Louisiana Third Circuit case, Dixie Roofing Co. of Pineville, Inc. v. Allen Parish Sch. Bd., 95-1526, 95-1527, (La.App. 3 Cir. 5/8/96), 690 So.2d 49, to support its argument that waivers of implied warranties are ineffective if they are issued after the completion of construction and discovery of the defect and are not contained in the initial sales contract. In Dixie Roofing, a school contracted to have its roof removed and replaced. Dixie, 690 So.2d at 51-52. Part of the materials used to replace the roof consisted of a single ply rubber membrane, manufactured by Firestone. Id. at 52. The roofing contract referred to Firestone's warranty, which required approval by Firestone on completion of the roof installation before it would be issued. Id. Before construction was complete and the warranty was issued, the school experienced heavy rainstorms, which caused the Firestone-manufactured rubber membrane to shrink, leading to severe leaking and damage to the school's interior. Id. Firestone alleged that it could not be subject to a redhibitory action, in part because the Firestone warranty, issued after construction was completed, precluded liability for redhibitory defects. Id. The court rejected this argument, finding that:

Id. at 53.

In this case, unlike in Dixie Roofing, in which the warranty and its limitations did not surface until after installation of the roof, there is at least some evidence that the Hospital had notice of the warranty waivers and limitations before the final warranty was issued. The issue in this case seems to be whether the warranty language in the submittals, transmitted to Bessette and Pomarico in 2001, put the Hospital on sufficient notice that implied warranties would be waived and the express remedies would be limited.

The Hospital cites to several different cases for the proposition that submittals that are not a part of the sales contract are ineffective to eliminate the requirement that waivers and limitations be in the sales contract. Most helpful to the court's inquiry is the Fifth Circuit case, Gulf South Mack., Inc. v. Kearney & Trecker Corp., 756 F.2d 377 (5th Cir.1985), in which a machine shop that made metal components for the oil industry ("GSM") bought a computerized machine designed for machining of metal components from a manufacturer ("K & T"). Id. a 378. Upon receipt of GSM's purchase order for the machine, K & T sent an acknowledgement form to GSM. Id. at 379. The front of the form contained a statement that it was an acceptance only upon the terms and conditions listed on the reverse side, and the reverse side contained a disclaimer of all implied warranties. Id. GSM filed the acknowledgement with their purchase order, but apparently was not made aware of the warranty clause at that time. Id. Unfortunately for GSM, upon receipt and installation of the machine, it immediately began to malfunction. Id. After several unsuccessful repair attempts by K & T, GSM asked for a replacement machine, but K & T refused. Id. GSM then sued for rescission of the sale, reduction of the purchase price, and damages because of the redhibitory defects. Id. At trial, the jury issued a verdict in favor of GSM. Id.

On appeal, K & T argued that the disclaimer of warranties against redhibitory defects, written on the back of the acknowledgement form, was binding on the parties. Id. at 379. GSM countered that the waiver was not a term of the contract because the form was extraneous to the contract of sale. Id. at 380. The Fifth Circuit sided with GSM, finding that the disclaimer of implied warranty against redhibitory defects was not binding on the parties, in part because it was very difficult for waivers that were not present in the contract of sale to be binding on the parties in light of the Prince line of cases:

Id. at 381. The Fifth Circuit also found that, even though "that the safeguards which protect nonbusiness consumers are more stringent than those protecting businessmen, a waiver of the warranty against redhibitory defects is nevertheless scrutinized very carefully to make sure that the third prong of the [Prince] test is satisfied even where the buyer is a businessman [like GSM]." Id. at 380-81.

In this case, it is difficult to apply the second prong of the Prince test to the facts of this case, because there does not appear to be an original "contract of sale." In the absence of an original contract of sale, the court must essentially jettison the second prong of the Prince test as inapplicable to the case at hand. Thus, the inquiry must ultimately turn on whether the relevant warranty provisions were brought to Pomarico's attention and explained to him (the third prong of the Prince test). This inquiry also provides unique problems which show that this case is distinguishable from most cases construing Prince. Unlike in many of the cases which follow Prince, this case deals with parties that are arguably more sophisticated than the average consumer. Additionally, while the Hospital, through Pomarico, had at least some notice of what the final Limited Warranty might look like, it is uncertain whether Pomarico knew that the terms in the submittals would definitely be the terms contained in the final Limited Warranty.

As noted by BASF, in its bid to become a subcontractor, Robbins submitted EIFS submittals to Pomarico and Bessette. Pomarico reviewed and then signed off on these submittals by initialing them. His one requirement was that the EIFS contain a ten year warranty, although at this point in the process, it does not appear that he required any other specifics on what the warranty might contain.

Turning to the substance of the submittals, they appear to show the various components of the EIFS system: the adhesive base coat, the finish coat, the waterproof membrane, etc.24 The submittals also explain how the various components of the EIFS system are assembled together to create the final product.25 The first submittal page that mentions warranties is on a page titled "Warranties: Drainage Systems." The warranty language on the "Drainage Systems" appears in small print at the bottom of the page and is as follows:

Unlike in the ultimate Limited Warranty that issued, however, the warranty language in the submittals provided for a five year warranty period (as opposed to ten year warranty period) and required the buyer to notify the seller within seven days of a breach of warranty (as opposed to thirty days). Further, unlike in the Limited Warranty, this "Drainage System" warranty says nothing about whether the EIFS will remain "fade, chip, flake and water-resistant for the warranty period." Like in the EIFS Limited Warranty, however, the "Drainage System" warranty limits remedies to replacement of the product or repayment of the purchase price.28 Additionally, like in the EIFS Limited Warranty, in the "Drainage System" warranty, the warrantor waives implied warranties of merchantability and fitness for a particular use.29

The submittals also contain a "10 Year Limited Warranty" for a product called Dens-Glass (which, as explained by BASF, is another component part of the EIFS system), although this warranty language is markedly different from the language in the final Limited Warranty. In the Dens-Glass warranty, it limits remedies to reimbursement for the cost of repair or replacement of the affected Dens-Glass sheathing panels, up to a maximum amount of two times the original purchase price.30 It also limits (but does not waive) implied warranties for a particular purpose and implied warranties of merchantability to the duration period contained in the warranty, or ten years.31

Ultimately, even construing the evidence in the light most favorable to BASF, the undersigned cannot find that these submittals put the Hospital on sufficient notice that implied warranties would be waived and remedies would be limited. As in the Gulf South case, even though the Hospital is a more sophisticated party than the average consumer, the third prong of the Prince test must be scrutinized very closely to ascertain whether Finestone brought these limitations to Pomarico's attention and explained them. While Pomarico signed off on the submittal documents as a part of Robbins' bid process, there is no evidence that Pomarico knew that the warranty language in the submittals would be ultimately binding on the Hospital — all he knew at that point is that he had requested a "ten year warranty," which would issue later.

Further, while there is some submittal language that does similarly exclude implied warranties and limit remedies, it appears on a page that is not entitled something to the effect of "Warranties: EIFS System," but rather is entitled "Warranties: Drainage Systems." Was Pomarico expected to know that this page, and the warranties contained therein, applied to the entire EIFS system, including the Finestone finish coat, absent an explanation from Finestone? Additionally, as noted supra, other language on the "Warranties: Drainage Systems" page is different from the ultimate Limited Warranty issued to the Hospital. Was Pomarico expected to know that the selective language limiting remedies and excluding implied warranties would reappear in the Limited Warranty, but that he should not expect the other terms (for example, the language on the "Drainage System" page requiring the buyer to give notice within seven days of a breach of warranty, as opposed to the buyer giving thirty days notice of a breach of warranty, as per the Limited Warranty) to appear in the Limited Warranty, absent an explanation from Finestone? Further, there is no explanation for why, instead, it would be unreasonable for Pomarico to expect that the remedies provided in the final Limited Warranty would instead be similar to those in the Dens-Glass portion of the submittals: namely, that the remedies would instead be limited to replacement or repayment of up to two times the purchase price, and that implied warranties would not be excluded, but instead would be limited in duration. Once again, Finestone never explained exactly what language in the submittals would ultimately be binding on the Hospital in the Limited Warranty. These discrepancies advise against a finding that the exclusions of implied warranties and limitations of remedies within the Limited Warranty, issued after discovery of the defect, are enforceable.

2. "Meeting of the minds" on waivers and limitations

The Hospital also asserts that, because the EIFS Limited Warranty was issued after the EIFS was sold and installed at the facility and the Hospital had reported the rust on the EIFS, it is apparent that the Hospital did not freely consent to the limitations and waivers contained in the warranty. As such, the Hospital alleges that BASF cannot retroactively limit or disclaim liability when it already knew of the complained-of defect.

BASF does not specifically refute this "meeting of the minds" argument, although it appears that BASF's arguments that the submittals were sufficient notice of what the Limited Warranty would contain could also apply to this argument.

The Hospital cites to Bieber-Guillory v. Aswell, 98-559 (La.App. 3 Cir. 12/30/98), 723 So.2d 1145, to support the general contention that "[w]hen there is no meeting of the minds between the parties, there is no enforceable contract." Id. at 1149-50. In Bieber-Guillory, an interior designer sued her customers after they failed to pay her for design services. The trial judge ruled in favor of the interior designer. Id. at 1148. On appeal, the Third Circuit agreed with the trial court that the interior designer was owed a debt, but that because the designer never reached an agreement on her fees and merchandise before she rendered her services (instead, the customers only received a bill after she had finished decorating), this lack of consent between the parties prevented the court from finding that an enforceable contract ever existed. Id. at 1150.

This issue goes back to whether and to what extent Pomarico understood that the language in the submittals would eventually resurface in the final Limited Warranty. The undersigned cannot say, based on the evidence before the court, that Pomarico consented to the exclusion of warranties and limitation of remedies. As noted supra, the submittals contain two different warranties (on the "Drainage System" page and the "Dens-Glass") page, with one excluding implied warranties and limiting remedies to a refund of the purchase price or replacement of the component product, and the other limiting implied warranties in duration and limiting remedies to a redund of two times the purchase price or replacement of the product. While Pomarico signed off on these submittals, the undersigned cannot find that, based on these submittals alone, Pomarico tacitly approved of the limitations on remedies and exclusions of implied warranties found in the final Limited Warranty.

3. Waiver of warranty limitations through Finestone's conduct in agreeing to remediate

The Hospital further alleges that even after the warranty issued, Finestone did not communicate the warranty limitations (either refund of purchase price or replacement of EIFS), instead opting to offer remedial pick and clean procedures to fix the rust stains. Because Finestone never asserted the warranty limitations until the filing of this lawsuit, the Hospital asserts that BASF cannot now hold the Hospital to those limitations. It also argues that BASF has effectively waived any right to claim that the warranty limitations are applicable, since, through its behavior, it clearly offered remedies that were not in the warranty for years (pick and clean), not asserting the warranty limitations until this case was filed.

BASF does not spend much time addressing these arguments, aside from arguing that the case law the Hospital cited is too different to be persuasive in this case. BASF essentially asserts that it did not waive any terms of the express warranty simply because, as "a gesture of goodwill," it offered the pick and clean remediation procedure to remedy the rust problem. When the Hospital finally grew weary of the pick and clean procedure and BASF's "goodwill," therefore, this was the first time that BASF could bring up the issue of options under the Limited Warranty. BASF offers that, in this instance, it will refund the purchase price of the Finestone EIFS finish coat, as per the dictates of the Limited Warranty.

The Hospital replies that, notwithstanding BASF's "goodwill" arguments, it is clear from the record that the rust issue was reported to Robbins as early as December 17, 2002; a complaint initiation form was submitted on December 30, 2002; and that Finestone knew, based on this information, that the finish coat was contaminated. It asserts that it only cost Finestone $12,300 to do the two pick and clean jobs (essentially, half of the cost of supplying a new finish coat), and thus Finestone was motivated by money, not goodwill, in offering the pick and clean option.

In this portion of its motion, the Hospital cites the unpublished Louisiana Second Circuit case, Sabbath v. Martin, No. 44,862, (La.App. 2 Cir. 10/28/09), 2009 WL 3449096. In Sabbath, the plaintiff bought a car from a used car dealership. At the time she bought the car, the Contract of Sale included a waiver of the warranty against redhibitory defects. Apparently there were issues with the car, because for the first three months that the customer possessed the car, she brought it in every other week to the dealership for repairs. At first, the dealership repaired the car for free, despite the waiver of implied warranties found in the Contract of Sale. Eventually, however, the dealership presented the plaintiff with a repair bill totaling $1,736.13 and requested one-half of the amount in cash for return of the car. The court found that the waiver of warranty against redhibitory defects in the Contract of Sale was unenforceable in part because the car dealership's behavior was confusing and inconsistent with the terms of the warranty:

Like in Sabbath, Finestone's behavior was inconsistent with the written terms of the Limited Warranty. As noted supra, the EIFS Limited Warranty waives all implied warranties and sets forth the two limited remedies (return of purchase price or replacement of the coating component) as the sole remedies available to the Hospital. Despite these express terms in the warranty, Finestone continued to remediate again and again. There is no explanation why, when the parties met in May 2008 and the Hospital indicated that the pick and clean remediation process was not working, Finestone did not assert at that time that perhaps a refund of the purchase price or replacement of the product would be the better solution — instead, it once again offered the pick and clean process.

This is further complicated by the fact that the offered pick and clean remediation added to the problem by picking holes into the EIFS wall. Relegating the Hospital to the remedies contained in the Limited Warranty leads to the absurd result that even though Finestone made the problem with the finish coat worse by picking apart the surface of the EIFS, it should only be on the hook for the original purchase price of the finish coat. These arguments are unpersuasive to the court, and thus BASF's liability cannot simply be limited to the purchase price of the finish coat, as BASF requests.

B. Construing Ambiguity in Written Warranty

Finally, the Hospital argues that even if the court finds the warranty limitations were not waived or made ineffective, the ambiguity of those provisions is construed in favor of the Hospital. As such, instead of BASF offering up its interpretation of a "replacement" of the product (pails of new finish coat), BASF should be required to replace the EIFS on the facility and throw in free labor and materials in order to do so. Because the court has found that the Hospital is not bound by the limited remedies within the Limited Warranty, however, its arguments in this section are moot.

II. BASF's Motion for Summary Judgment

As the court has found that the waiver of implied warranties and limitation of remedies was ineffective, the court will next turn to the arguments in BASF's motion: (1) whether the Hospital has a valid claim for breach of implied warranty against redhibitory defects under La. Civ. Code Ann. art. 2520; (2) whether the prescriptive period on the Hospital's redhibition claim has expired; (3) whether the Hospital has a valid claim for breach of implied warranty that the product is fit for ordinary use under La. Civ. Code. Ann. art. 2524; (4) whether the Hospital waived its claims under the warranty by failing to report the rust within thirty days; (5) whether BASF is liable for the Utility building, on which Robbins performed remediation work; and, (6) whether BASF is entitled to choose between the two options in the written EIFS Limited Warranty (either refund of purchase price or replacement of EIFS top coat).

A. Redhibition Claim

1. Redhibition does not require a direct buyer/seller relationship

BASF attacks Hospital's redhibition claim, arguing that under La. Civ. Code Ann. Art. 2520, the Hospital cannot prove the requisite buyer/seller relationship needed for a redhibition claim. Allegedly, because the EIFS was incorporated into the final product (the facility) via a construction contract before the Hospital took control of the facility, there was no sale of the EIFS from Finestone to the Hospital, and thus it follows that there was no buyer/seller relationship. BASF also cites heavily in this portion of its motion to the Louisiana Fourth Circuit case, K.E. Pittman v. Kaiser Aluminum Chemical Corp., 559 So.2d 879 (La.App. 4 Cir.1990) to support its argument that if a product (like EIFS) is incorporated into a building during construction, but before ownership of the building is transferred, a plaintiff cannot pursue a redhibition claim against the manufacturer of that component part.

The Hospital counters that a party can assert a direct cause of action in redhibition against both the seller of the product and the manufacturer. The Hospital then notes that the "component part" argument by noting that the case that BASF relies on (Pittman) to make its argument has not been accepted by other courts.

BASF replies that the clear language of art. 2520 limits redhibition actions to those between a buyer and a seller, and that in the cases cited by the Hospital in which a manufacturer was liable under a redhibition theory, there was a "nexus" between the plaintiff and the defendant-manufacturer lacking in this case; namely, that those plaintiffs had contracted themselves for the installation of the product at issue and/or specified the particular product for use. In this case, instead, the Hospital contracted for construction and delivery of a completed building and delegated to its architect, Pomarico, and its contractors, Bessette and Robbins, the full responsibility for selecting products such as EIFS.

Article 2520 does indeed provide that "[t]he seller warrants the buyer against redhibitory defects, or vices, in the thing sold." La. Civ. Code Ann. art. 2520 (emphasis added). The question thus becomes whether courts construing this article read this provision to be very narrow such that it only includes direct buyer/seller relationships. The court finds that it has not.

Turning to the cases that BASF cited to support its argument that redhibition requires a buyer/seller relationship, many of the cases that BASF cites do not shed any light on the rights of a buyer who purchases a product through a subcontractor or contractor middleman.32 Additionally, the cases BASF cites for the proposition that a redhibition claim requires vendor/vendee relationship additionally do not seem to provide guidance on whether a consumer has a valid redhibition claim against a manufacturer.33

The Hospital has cited several cases that support the argument that a buyer may pursue a redhibition claim against a manufacturer. For example, in Moreno's, Inc. v. Lake Charles Catholic High Sch., Inc., 315 So.2d 660 (La.1975), a subcontractor filed a suit against a building owner for costs of replacing an air conditioner compressor, and the owner then filed a third party cause of action against the compressor's manufacturer. Id. at 661. The Louisiana Supreme Court held that the third-party plaintiff (building owner) had a viable direct right of action against the manufacturer under the seller's (contractor) accessory right of action, as the seller had proven a redhibitory defect. Id. at 663. Additionally, in Aucoin v. S. Quality Homes, LLC, 2007-1014 (La.2/26/08), 984 So.2d 685, the Louisiana Supreme Court held that a buyer may pursue a redhibition cause of action against a manufacturer when the manufacturer is directly liable for defects resulting from the original manufacture of the defect. Id. at 693.

In this instance, it is clear that the Hospital may pursue a direct cause of action under art. 2520 against the manufacturer, BASF. While BASF focuses on the specific buyer/seller language in art. 2520 for its argument that the Hospital is not a proper party, it ignores case law that has established that a manufacturer may be directly liable to a building owner for redhibitory defects, even if a third party middleman actually purchased the products. Further, BASF's argument that the Hospital did not specifically contract to buy the EIFS (and thus there is no "nexus" between the Hospital and BASF to allow for a redhibition claim) does not hold water. While the Hospital delegated the selection and purchase of EIFS and other building materials to its architect and its contractors, these actors acted as agents for the Hospital. Not permitting redhibition claims just because a building owner delegates the purchases of certain products to third party agents would prevent building owners from ever pursuing redhibition claims against manufacturers in construction cases. BASF's reading of art. 2520 is thus too limited to be persuasive.

Further, as pointed out by the Hospital, the "component part" argument BASF cites from the case Pittman v. Kaiser Aluminum, 559 So.2d 879 (La.App. 4 Cir. 1990) has been rejected by other courts. In Pittman, the plaintiff sued the manufacturer of certain wiring components installed in his new home after it was destroyed by fire, alleging that faulty wiring led to the disaster. Id. at 1182. The Court of Appeals upheld the exception of no cause of action, finding no vendor/vendee relationship existed between the building owner and the component part manufacturers. Id. at 1183. In both the Eastern District of Louisiana and the Western District of Louisiana, however, courts have rejected the Pittman argument that a component part manufacturer cannot be liable in a redhibition cause of action because of lack of vendor/vendee relationship. See Howard Pardue v. Cummins, Inc., No. 08-1677, 2009 WL 5171462 (E.D.La. Dec. 17, 2009) ("Given that the Louisiana Supreme Court has never precluded a cause of action in redhibition against a component part manufacturer, and to the contrary has interpreted the statute liberally, this Court finds that [the plaintiff] does state a claim against Defendants in redhibition"); accord, RTT Truck Repair, LLC v. Paccar, Inc., No. 091105, 2011 WL 865582 (W.D.La. March 10, 2011). BASF's argument that it can escape a redhibition claim because it only manufactured a defective component part thus similarly fails.

2. The rust on the EIFS was a redhibitory hidden defect

BASF also argues that the Hospital's redhibition claim fails because it has failed to establish the required element of a "hidden defect" under La Civ. Code Ann. art. 2521. BASF argues in this portion of its motion that because the rust stains were visible prior to substantial completion of the facility, and prior to the Hospital acquiring ownership of the buildings, the Hospital had clear knowledge of the non-hidden rust defect before it ever acquired ownership of the EIFS as a component part of the facility.

The Hospital counters that it is undisputed that iron pyrite particles are impossible to detect and remove from the finish coat until they start to rust, and that this did not happen until the EIFS was installed and the particles began to rust from exposure to the elements. Next, the Hospital argues that BASF's argument that the Hospital knew about the rust before transfer of ownership from Bessette to the Hospital is also misplaced: instead, the Hospital has always owned the facility, and ownership never "transferred" from Bessette to the Hospital. Additionally, it argues that BASF misunderstands the "time of sale" language from art. 2521 and ignores the fact that the rust originally appeared after the EIFS components were installed on the facility walls. For the Hospital, the relevant transaction for the purposes of art. 2521 was therefore not the date of substantial completion of the facility or the date that the Hospital took possession of the completed facility, but rather the date when Finestone put the EIFS into commerce through its distributor, F & W.

The relevant provision of the Louisiana Civil Code that BASF relies on for this portion of its argument is as follows: "[t]he seller owes no warranty for defects in the thing that were known to the buyer at the time of the sale, or for defects that should have been discovered by a reasonably prudent buyer of such things." La. Civ. Code Ann. art. 2521 (emphasis added). BASF cites a few cases to support its argument that when a defect is apparent at the time of sale, it cannot be a redhibitory defect. Turning to these cases, however, it is apparent that they are distinguishable from the one here.34

In its reply, the Hospital cites one case, Theriot v. Commercial Union Ins. Co., 478 So.2d 741 (La.App. 3 Cir.1985) to support its conclusion that the relevant transaction date for the purposes of art. 2521 is not the date the Hospital took possession of the completed facility, but rather the date that the manufacturer, Finestone, put the product into commerce through it distributor. While the Theriot court does not specifically make this holding, the reasoning in it is persuasive to the inquiry in this case, because the court held that the purchaser, who may have not even been involved in the initial purchase of the product, can still recover for breach of implied warranties against the original seller. In Theriot, the court noted that

Id. at 745-46 (internal citations omitted).

Additionally, in Dixie Roofing, the Louisiana Third Circuit found that the plaintiff school board was entitled to the inference that a redhibitory defect in the roof on its school building existed at the time of sale. 690 So.2d at 55. In Dixie Roofing, like in this case, the roofs defect did not become apparent until after the roof was sold and installed on the building, where it then promptly shrank after exposure to the elements. Id.

In this case, BASF argues that the point of sale was when the Certificate of Substantial Completion was issued on December 19, 2002. Thus, because the Hospital accepted the building at that point, even though the EIFS rust was apparent (as noted supra, the Hospital first noticed the rust on December 17, 2002), it waived its redhibition claim. It supports this allegation by citing to several admissions by various parties affiliated with the Hospital, during their depositions, that they assumed that, when the Certificate of Substantial Completion was issued, ownership of the building was transferred from the contractor to the Hospital. The Hospital counters this by producing the construction contract between Bessette and the Hospital, and a companion affidavit from the president of Bessette, in which she states that "at no time did Bessette own the hospital buildings, and at no time did Bessette execute any document translative [sic] of ownership of those buildings."35

For the purposes of this argument, BASF appears to present a rather contorted version of the facts to make the argument that the defect was apparent at the "time of the sale," characterizing the Certificate of Substantial Completion as the relevant transaction date. At the time the EIFS was purchased from Finestone through the EIFS supplier, F & W, for installation on the facility, there is no allegation that the rust stains were present. It was not until later, when the EIFS was installed and thus exposed to the elements, that the rust stains became apparent and the defect "manifested" itself. If, instead, the rust had been apparent at the time F & W had shipped out the EIFS, then of course the Hospital would not have a valid redhibition claim. But in this instance, it is clear that, after the purchase and installation of the EIFS, the defect manifested itself. The Certificate of Substantial Completion date is entirely irrelevant to when the purchase date for the EIFS was for the purposes of ascertaining whether the rust was hidden at that point or not. Construing the evidence in the light most favorable to the Hospital, the defect was hidden at the relevant time of sale, and thus the iron pyrite constitutes a redhibitory defect.

B. Prescription of the Hospital's LPLA, negligence, and redhibition claims

BASF primarily relies on its prescription argument, asserting the argument in its Motion for Summary Judgment and as a counter-argument in its opposition to the Hospital's Partial Motion for Summary Judgment. BASF alleges that the Hospital's negligence, breach of implied warranty against redhibitory defects, and Louisiana Products Liability Act ("LPLA") claims are all prescribed, since the prescriptive period for each of these claims is one year, "whether based on assertions of negligence in the manufacture of the product or in the remediation process."

1. The LPLA and negligence are irrelevant to the Hospital's cause of action.

At the outset, BASF's argument on the prescriptive period for tort-related LPLA and negligence claims is a red herring. This cause of action is for purely economic damages accruing because of damage to the product itself, and thus falls under the ambit of redhibition, not tort claims. See La. Civ. Code. Ann. art. 2520 ("A defect is redhibitory when it renders the thing useless, or its use so inconvenient that it must be presumed that a buyer would not have bought the thing had he known of the defect. The existence of such a defect gives a buyer the right to obtain rescission of the sale."). As one leading treatise on the LPLA explained, when distinguishing a redhibition claim from a tort-related LPLA claim:

John Kennedy, A Primer on the Louisiana Products Liability Act, 49 La. L. Rev. 565, 580 (1989). It seems clear in this instance that the Hospital is proceeding under a redhibition claim, not an LPLA tort claim, because the economic loss arises from the product itself, and not damage to other property or damage from personal injury. Further, there is no evidence that the Hospital cannot proceed in redhibition, which would be the only instance where it would be allowed to proceed under the LPLA instead.

For similar reasons, this cause of action does not seem to present a generic tortious negligence claim. Even if the undersigned assumed that this cause of action sounded in tort, a negligence claim would not be available. The LPLA establishes the exclusive theory for liability against manufacturers for products liability tort claims, and negligence is not an available theory of liability under the LPLA. See La.Rev.Stat. Ann. 9:2800.52; see also Jefferson v. Lead Indus. Ass'n, Inc., 106 F.3d 1245, 1251 (5th Cir.1997). Accordingly, BASF's arguments relating to the LPLA and negligence are irrelevant to the Hospital's cause of action.

2. The prescriptive period for the redhibition claim has not expired

Turning to the parties' arguments on redhibition prescription, BASF asserts that the Hospital has been aware of the defect in the EIFS since 2002, and thus if the redhibition prescriptive period began to run from that date, then certainly it ran out by August 2010.36 In the alternative, assuming the prescriptive period began to run from the last time the parties communicated with each other (the August 5, 2008 letter that Pomarico sent to Finestone, but Finestone allegedly never received), BASF alleges that the prescriptive period has still passed, since the Hospital did not file the lawsuit until over a year and a half later.

The Hospital counters that the prescriptive period did not begin to run because Finestone continued offer the pick and clean remediation process again and again. It alleges that Finestone failed to comply with the requirements of La. Civ. Code Ann. art. 2534(C),37 by failing to inform the Hospital that it refused or was unable to make repairs after the alleged stalemate on whether a third pick and clean attempt should be done. Further, the Hospital notes that it never clearly refused further remediation attempts (and that the August 5, 2008 letter actually offered that the Hospital would try a "sample" pick and clean), indicating that there was still a chance that Finestone might remediate again. The Hospital argues that the earliest date that the clock could start to run on the prescriptive period was August 19, 2010, the date when Finestone unilaterally closed its file on the Hospital (and thus closed off the chance of further remediation efforts). The Hospital then cites to the other pick and clean remediation efforts, noting that there was always a long lag period between the Hospital giving Finestone notice of the rust stains and Finestone actually starting the pick and clean process.38 Based on this, the Hospital asserts that when "a defendant in a redhibition action consistently assures the plaintiff that it will remedy the problem, and repeatedly attempts repairs, the defendant has not abandoned repair efforts."

BASF replies that, in general, courts addressing interruption of prescription under art. 2534 look to the date repairs were last made to determine when prescription began to run. Thus, BASF asserts that "there is no mystical quality to the phrase `abandonment' of repairs ... prescription occurs when the last repairs are completed." As such, the last round of repairs was in May 2006, and the prescriptive period began to run from then. It also argues that the interactions the parties had in 2008 (regarding the third potential pick and clean) could not be clearly seen as a continuance of Finestone's attempts to remedy the problem, particularly because BASF considers the May 2008 meeting as a rejection of Finestone's offer to do a third pick and clean. BASF further rejects the argument that Pomarico's letter, requesting a "sample" pick and clean, kept the remediation time window alive: it asserts that Finestone never agreed to do a sample pick and clean, and instead only offered to pick and clean the entire Hospital building and Medical Office building. Concluding, BASF asserts that the Hospital "cannot meet its burden of establishing prescription was interrupted. Its claims, filed over four (4) years after repairs were last performed and nearly two years after the parties failed to reach an agreement on repairs, are prescribed."

The main issue here is fairly straightforward: when, in the variety of dates offered by the parties, did the prescriptive period on the redhibition claim actually begin to run? Article 2534, which addresses prescription of redhibition claims, provides:

La. Civ. Code Ann. art. 2534.

First, it is apparent that the redhibition prescriptive period did not begin to run from the time the Hospital discovered the defect in the EIFS 2002: allowing the prescriptive period to run from the date of discovery would entirely ignore Finestone's continued attempts to repair via the pick and clean process, and would punish the Hospital for allowing Finestone to remediate.

The parties have cited several cases to guide the court's inquiry. For example, in PPG Indus., Inc. v. Industrial Laminates Corp., 664 F.2d 1332 (5th Cir.1982), a subcontractor sued a supplier of wall panels when it discovered the panels were defective. Id. at 1334. The supplier attempted to remedy the situation by sending the subcontractor replacement panels, the last of which were received in March 1976. Id. The Fifth Circuit held that normally, the prescriptive period would begin to run from the date the defect was discovered, but in this instance, it would begin to run from the last time the supplier offered replacement panels. Id.

In Huckabee v. Sunshine Homes, 26,294, (La.App. 2 Cir. 12/7/94), 647 So.2d 409, purchasers of a mobile home made several complaints about the leaky ceiling in their mobile home, purchased in 1984, to the mobile home manufacturer. Id. at 411. The manufacturer serviced the mobile home several times in 1985 and 1986, finally refusing to service the home again in 1986 because the warranty had expired. Id. The purchasers continued to have problems with the home, but attempted to repair them themselves because of the manufacturer's earlier refusal to continue repairs. Id. Eventually, in 1989, the purchasers once again asked the manufacturer to repair the home, but it once again refused. Id. at 412. The Louisiana Second Circuit held that the redhibition prescription period began to run in 1986 when the manufacturer abandoned its attempts at repairs. Id. at 413. It also held that the purchasers' request in 1989 to do more repairs did not revive the prescriptive period, as the manufacturer had not "clear[ly], direct[ly], and absolutely]" renunciated prescription by taking up repairs again. Id.

In Dixie Roofing, the Louisiana Third Circuit found that the prescription period for the plaintiffs redhibition had not expired because the defendant-manufacturer, Firestone, had continued to offer repairs. Concluding, the court found that

Dixie Roofing, 690 So.2d at 54.

This "last date of repairs" rule must be tempered by another rule from Louisiana jurisprudence that "interruption of prescription will occur when there has been verbal or written communication which would reasonably lead a buyer to believe that the defects complained of would be remedied." In re Sigma Services Corp., 16 B.R. 611 (Bankr.M.D.La. 1981) (citing Weaver v. Fleetwood Homes of Mississippi, Inc., 327 So.2d 172 (La. App. 3 Cir.1976) (emphasis added)). For example, in In re Sigma Services Corp., the bankruptcy court denied summary judgment on the defendant's redhibition prescription argument, noting that there was no evidence to corroborate the plaintiff-buyer's state of mind on whether he believed that the defendant would remedy problems with a truck he had bought from the defendant. See id. at 614. In Ory v. A.V.I Const., 03-72 (La.App. 5 Cir.5/28/03), 848 So.2d 115, the Louisiana Fifth Circuit held that, when a defendant made repeated attempts to repair faulty sheetrock on a plaintiffs home, and then finally told them he could "do nothing else for them," the plaintiffs' subsequent letters to the defendant asking for a meeting to resolve the issues did not pause the redhibition prescription period. Id. at 120.

In this case, the last repairs were done in May 2006, but there is clear evidence that the parties were still willing to continue the remediation process after that date, and that the Hospital was under the reasonable belief that remediation would continue. The parties met again in May 2008 to discuss a potential third pick and clean. Despite the Hospital's alleged disinterest during the May 2008 meeting in pursuing a third pick and clean and its and request to instead replace all of the EIFS, Finestone sent a follow up letter in June 2008, memorializing in writing the offer to pick and clean a third time. Pomarico then sent the reply letter in August 2008, requesting a "sample" pick and clean. Based on the interactions of the parties, it appears that, construing the evidence in the light most favorable to the Hospital, the Hospital (through Pomarico) reasonably believed as of August 2008 remediation would continue. Pomarico did not completely reject the offer of a third pick and clean, he simply asked for a sample pick and clean to see if it would be effective before signing on to a pick and clean of the entire facility.

The issue of prescription is further complicated by the fact that the Hospital was accustomed to a long lag time between complaining about the rust and Finestone doing something about it: as noted supra, for the first pick and clean, the Hospital complained in December 2002, and the pick and clean occurred in May 2003. For the second pick and clean, the Hospital complained in December 2004 and the pick and clean did not occur until May 2006, a full year and a half later. The Hospital explained during oral argument that because it was accustomed to such a long lag time, it did not immediately check with Finestone about the pick and clean process after the June 2008 and August 2008 letters. Additionally, it asserted that Finestone continued to mislead it into thinking that the pick and clean process would eventually work, thus advising against filing suit.

In this case, there is evidence that the Hospital reasonably believed that remediation would continue after the August 2008 letter, thus pausing the prescriptive period on any redhibition claim. Construing the evidence in the light most favorable to the plaintiff, the undersigned cannot find that this fact pattern necessitates dismissal of the Hospital's redhibition claim by reason of prescription.

C. Breach of Implied Warranty for Fitness for Ordinary Use under Article 2524

1. Article 2524 applies to the Hospital's claims.

(a) Rust on the EIFS renders it "unfit for ordinary use" under article 2524, and article 2524 and redhibition claims are not mutually exclusive

BASF notes that the Hospital has asserted a claim under La. Civ. Code Ann. art. 2524, alleging that BASF has breached the warranty that the EIFS is fit for ordinary use. BASF first asserts that the Hospital has acknowledged that the EIFS is capable of its ordinary use under art. 2524 — being used as a wall cladding system — and thus it does not have a viable art. 2524 claim. Related to this, BASF asserts that Louisiana law only allows a claim for breach of contract for fitness of ordinary use under art. 2524 when an item is free of redhibitory defects. Since the Hospital is claiming the rust stains as a redhibitory defect, therefore, the Hospital's art. 2524 claim must fail.

The Hospital counters that BASF ignores a basic requirement for the EIFS in concluding that it was still "fit for ordinary use" under art. 2524: that the walls were also chosen to have a specified color and texture, and that BASF markets and specifically warrants the aesthetic nature of the EIFS wall system. As such, the aesthetic nature of the wall was a "critical component," and thus the EIFS was not fit for ordinary use when it became rusty and lost its color. The Hospital also counters that BASF is incorrect in asserting that claims under art. 2524 and 2520 are mutually exclusive: citing to an unpublished 2011 case decided by Judge Drell, Justiss Oil Co., Inc. v. T3 Energy Servs., Inc., No. 1:07-cv-01745, 2011 WL 539135 (W.D.La., Feb. 7, 2011), the Hospital asserts that the majority of Louisiana Appellate Courts have found that a party can assert both a claim for breach of warranty against redhibitory defects under art. 2520 and a breach of warranty for fitness for ordinary use under art. 2524.

BASF replies that it is still clear, based on the facts, that the EIFS is fit for its ordinary use (as an exterior cladding system), and that the Hospital is once again confusing a redhibitory action with an art. 2524 action. BASF also argues that the real reason the Hospital is making an art. 2524 claim is because the prescriptive period is longer (ten years) than the prescriptive period for a redhibition claim (one year), and the redhibition claim has already gone stale. BASF also notes that in the Justiss case the Hospital cites for the proposition that art. 2524 and redhibition claims are not mutually exclusive, all of the cases the Justiss court cited for that proposition were decided before art. 2524 was enacted, which was specifically intended to clarify confusion between redhibition and art. 2524 claims. Citing to a Louisiana Third Circuit case, Cunard Line Ltd. Co. v. Datrex, Inc., 05-1171, (La.App. 3 Cir. 4/5/06), 926 So.2d 109, BASF notes that when a plaintiff asserts both a redhibition claim and an art. 2524 claim, and it is clear that the art. 2524 claim is only asserted to take advantage of the longer prescriptive period, the art. 2524 claim will be subsumed by the redhibition claim.

This issue presents an interesting question that the Louisiana Supreme Court apparently has not yet been answered: when a party alleges that a product has a redhibitory defect (art. 2520), can it also argue that the redhibitory defect renders the product unfit for its ordinary use (art. 2524)?

Article 2524 provides:

La. Civ. Code Ann. art. 2524.

Article 2524 was enacted in 1995, and the Revision Comments further provide:

Id.

As discussed supra, a redhibitory defect is defined as something that renders a product "useless, or its use so inconvenient that it must be presumed that a buyer would not have bought the thing had he known of the defect [or] without rendering the thing totally useless, it diminishes its usefulness or its value so that it must be presumed that a buyer would still have bought it but for a lesser price." La. Civ. Code Ann. art. 2520.

BASF relies on the reasoning from the 2006 Louisiana Third Circuit case, Cunard, for the proposition that art. 2520 claims and 2524 claims are mutually exclusive. In Cunard, a cruise ship owner (Cunard) bought a lighting system from a supplier (Dartex) for its line of cruise ships. Cunard, 926 So.2d at 111. The lighting systems were defective and shorted out, however, prompting Cunard to sue Dartex. Id. Dartex then filed an exception of prescription, arguing that since Cunard had brought a redhibition claim, and more than one year had passed since discovery of the defect, Cunard's claim was prescribed. Id. Cunard argued that instead it was bringing an art. 2524 claim, which had a ten year prescriptive period, and thus prescription had not run. Id. at 111-12. The trial court agreed with Dartex, and granted the exception of prescription. Id. On appeal, the Louisiana Third Circuit first noted that while some of the language in Cunard's petition seemed to indicate that the lighting system was "not fit for ordinary use" on a cruise ship, this assertion was based on the reasoning that it was not fit for ordinary use because the lighting system was defective in design. Id. at 113. Continuing, it noted that

Id. The court then reviewed the legislative history of art. 2524 to determine whether 2524 or 2520 applied to the cause of action, or both, and found that the Louisiana legislature had intended to create a separate and distinct cause of action from art. 2520 by enacting art. 2524. Id. at 13-14.

In contrast, the Hospital leans heavily on the reasoning from the Justiss case, which distinguished itself from Cunard, to support its arguments here. In Justiss, Judge Drell addressed whether the owner/operator of a well, who alleged that a defective well head component had ruined fracking operations, could assert both a claim for breach of warranty against redhibitory defects under art. 2520 and a breach of warranty for fitness for ordinary use under art. 2524. Justiss, 2011 WL 539135 at *1. In finding that the plaintiff could assert both causes of action, Judge Drell first noted that he would reject the reasoning in Cunard and instead follow the "majority of Louisiana appellate courts," which had found that an art. 2520 and art. 2524 claim were not mutually exclusive. Id. at *5. Further, Judge Drell specifically distinguished Cunard from the Justiss case, noting that in Cunard, the court was required to decide whether either art. 2520 or 2524 applied because the prescriptive periods were different and the shorter prescriptive period for the art. 2520 claim expired. Id. Concluding, Judge Drell noted that

Id. at *6.

As in the Justiss case, the undersigned declines to follow the holding in Cunard. First, like in Justiss, the court has found that the one-year prescriptive period on the Hospital's redhibition claim has not expired, and thus the Hospital is free to assert claims under both art. 2520 and art. 2524 in the absence of conflicting prescriptive periods. Further, while BASF argues that rust on the EIFS is simply a redhibitory defect and that this defect does not render the EIFS unfit for ordinary use, the undersigned is persuaded by the Hospital's argument that a main criteria for the EIFS was for it to be aesthetically pleasing. An exterior wall which is riddled with rust spots is certainly not fit for the ordinary use of presenting a certain aesthetic to the outside world. Accordingly, the Hospital has pled a valid art. 2524 claim.

(b) Article 2524 does not require a buyer/seller contractual relationship.

Next, BASF argues that the Hospital does not have a contractual relationship with BASF that would trigger the provisions of art. 2524, and that art. 2524 requires a relationship between a "buyer" and a "seller." Here, BASF asserts that the Hospital was not the "buyer" of the EIFS, "but rather acquired [it] as a component part of the New Hospital buildings via a contract of construction."

The Hospital counters that BASF is incorrect in arguing that art. 2524 requires privity of contract between a buyer and a seller. It asserts that in this instance: Finestone put the EIFS materials into commerce; then, the intermediaries (F & W and Robbins) installed it; and finally, the Hospital received the finished project. Just because there was a "middleman" between the buyer-Hospital and seller-Finestone, this does not shield BASF from liability.

Much like BASF's argument that a redhibition claim requires a direct buyer/seller relationship, the undersigned also finds here that BASF's reading of the buyer/seller component of art. 2524 is too limited to be persuasive and is in contravention to established jurisprudence in Louisiana. See Media Production Consultants, Inc. v. Mercedes-Benz of N. America, Inc., 262 La. 80, 262 So.2d 377, 381 (1972) (holding that a consumer without privity can recover against Mercedes-Benz, the car distributor, even though the plaintiff bought the car through a "conduit'Vfranchise dealer). In this case, while the Hospital bought the EIFS through intermediaries (F & W selling the EIFS to Robbins, who then installed it on the facility), this lack of direct privity cannot shield BASF from liability under art. 2524.

2. The LPLA is irrelevant to this cause of action, and thus has no effect on the art. 2524 claim

BASF concludes that a claim under art. 2524 and is "subsumed and precluded by the LPLA," which, as argued above, has a prescriptive period of one year. For the reasons discussed supra, this is not an LPLA claim. The damage asserted here is to the product itself, not damage to other property or damage from personal injuries (which sounds in tort). Further, the undersigned agrees with the Hospital that there is an essential element missing here which is required for an LPLA claim: unreasonable dangerousness. Thus, this LPLA argument is irrelevant.

D. Effect of the Hospital's failure to report the rust within thirty days, as per the dictates of the written warranty, and effect of Robbins performing remediation work on the Utility building

Next, BASF argues that the Hospital does not have a valid claim against BASF under the written EIFS warranty39 because it failed to comply with the warranty's terms and conditions. It notes that the Hospital breached the warranty by failing to notify BASF within thirty days of the rust stains, and that the first time the stains appeared, the Hospital did not complain about them until a year and a half after they had first become visible (May 2003 — December 2004). After the second remediation effort, the Hospital was allegedly guilty of a lapse between seeing the stains and complaining (May 2006 — end of 2007). BASF also avers that, because Robbins used non-BASF products to repair the Utility building in 2005, this frees BASF from any obligation to fix the Utility building because Robbins using non-BASF products violates an express term of the warranty. BASF argues that the Robbins alterations "caused additional and distinctive stains/blemishes to the exterior cladding of the building, causing it to be worse in appearance than the other buildings."

The Hospital counters that "there is no dispute that [the Hospital] made its original complaint to [Finestone] timely and that [Finstone] accepted liability." It asserts that the rust spots appeared gradually over time, and that, after the first pick and clean process, it had been advised by Finestone to "wait and see" whether new rust spots would develop, which explains why it waited a long time to complain after the first and second pick and clean procedures. It further notes that at no time did Finestone assert the thirty-day limitation, instead opting to acknowledge responsibility for the problems and trying to fix it via the pick and clean process. In regards to the Utility building, the Hospital asserts that nothing Robbins did to remediate the Utility building post Hurricane Rita caused the rust stains. Instead, all fault remained with Finestone, because the stains were solely caused by the iron pyrite which had always been in the EIFS.

As noted earlier in this ruling, the Hospital has a clear excuse for not objecting within the thirty day time window: the rust slowly appeared over time. The Hospital complained almost immediately the first time the rust stains appeared in December 2002. Additionally, there is evidence that Finestone told the Hospital to wait and see whether the rust issue would get worse or not after the first and second pick and clean attempts. Construing the evidence in the light most favorable to the Hospital, there is plentiful evidence that the Hospital waited to act because of Finestone's continued offers of repairs. A finding now that the Hospital waived its rights under the warranty because it failed to assert them within the thirty-day time window would essentially penalize the Hospital for allowing Finestone to continue to offer repairs.

Further, summary judgment on the issue of whether BASF is liable for the problems with the Utility building is premature. There is a contested issue of material fact on whether the rust stains were solely caused by the manufacturing defect in the EIFS or else by negligence on the part of Robbins instead.

E. BASF's right to pick between two options in written warranty

BASF's final argument is that, if the court determines that the Hospital has a written claim under the EIFS warranty, it has the right, per Louisiana law and the EIFS Limited Warranty, to choose between the two alternative options set forth in the warranty (either replacement of the coatings or refund of the purchase price). Thus, if the court decides that BASF is liable under the express warranty, BASF wishes to pick the option of refunding the purchase price of the EIFS ($22,960.00).

BASF's arguments operate on the assumption that the written EIFS Limited Warranty is absolutely binding on the parties, and thus it gets to choose which remedy option it can offer to the Hospital. As noted supra, there are clear problems with the EIFS warranty, however, which render the limitations on remedies ineffective. Accordingly, BASF's arguments in this portion of its motion are moot.

CONCLUSION

In conclusion, the court grants the Hospital's motion, finding that the Limited Warranty's exclusion of implied warranties and limitation of express remedies are unenforceable. Additionally, the court denies BASF's motion, finding that the Hospital has valid redhibition and art. 2524 claims, that the redhibition claim is not prescribed, that the Hospital's failure to assert a breach of warranty within the thirty-day window prescribed by the Limited Warranty has no effect on the Hospital's claims, and that it is premature to grant summary judgment on whether BASF is liable for the damage to the Utility building.

MEMORANDUM ORDER

Before the court is a Motion to Alter or Amend Judgment [Doc. 63], filed by the defendant, BASF Construction Chemicals, LLC ("BASF"). The plaintiff, Southwest Louisiana Hospital Association ("the Hospital") filed an opposition [Doc. 67]. For the foregoing reasons, BASF's motion is GRANTED. The previous Memorandum Ruling [Doc. 62] and accompanying Judgment [Doc. 60] are amended as reflected in this Memorandum Order.

PROCEDURAL BACKGROUND

As the undersigned summarized the relevant factual background in the preceding ruling on the parties' cross summary judgment motions, the entire fact pattern will not be repeated here. Briefly, this case arises out of the installation of a defective architectural wall system, known as Exterior Insulation Finish System ("EIFS"),1 at the Hospital's facility on Nelson Road in Lake Charles, Louisiana.

In the court's previous ruling, the court made several findings, although only a few are relevant to the motion at bar. Addressing the Hospital's Partial Motion for Summary Judgment, the court first found that BASF's attempt to limit remedies and waive implied warranties was ineffective because BASF could not satisfy the third prong of the waiver of warranties/remedies test (whether the waivers and limitations found in the Limited Warranty were pointed out and explained to the Hospital) found in the seminal Louisiana Supreme Court case, Prince v. Paretti Pontiac Company, 281 So.2d 112 (La.1973).2 Relying on this finding, the court next affirmatively found that there was no "meeting of the minds" on waivers and limitations;3 that Finestone had waived warranty limitations based on its conduct in agreeing to remediate;4 and, that, since it had found the Limited Warranty unenforceable, it was unnecessary to discern whether any potential ambiguities within the Limited Warranty should be construed in favor of the Hospital.5 In sum, the court granted the Hospital's motion in its entirety.6

Turning to BASF's Motion for Summary Judgment, the court found that it could not dismiss the Hospital's article 2520 breach of warranty against redhibitory defects claim ("redhibition claim") based on prescription, as there was evidence that BASF continued to offer repairs, thus pausing the prescriptive period.7 Additionally, finding persuasive the reasoning in the Western District of Louisiana case, Justiss Oil Co., Inc. v. T3 Energy Servs., Inc., No. 1:07-cv-01745, 2011 WL 539135 (W.D.La., Feb. 7, 2011), the court found that the Hospital could also assert an article 2524 claim ("breach of warranty that the thing is fit for ordinary use") for two reasons: (1) a redhibition claim under article 2520 and an article 2524 claim were not mutually exclusive, and (2) because the court had found that the shorter redhibition prescription period had not passed, the Hospital was free to assert both redhibition and article 2524 claims.8 Thus, the court denied BASF's motion in its entirety.9

BASF now moves to alter or amend this court's ruling on the cross motions for summary judgment, requesting clarification on the portions of the opinion discussed immediately above, as well as clarification on the Judgment which accompanied the summary judgment Memorandum Ruling.10

MOTION TO ALTER OR AMEND JUDGMENT UNDER RULE 54(b)

At the outset, the undersigned notes that BASF has erroneously moved under Rule 59(e) to alter or amend this court's previous ruling. While Rule 59(e) allows a party to alter or amend a judgment, this rule pertains specifically to final judgments. In this case, the court's ruling on the cross motions for summary judgment was not the final judgment of the court, and thus BASF's motion is more properly analyzed under Rule 54(b), which provides that

FED.R.CIV.P.54(b) (emphasis added).

Addressing a similar procedural situation, Judge Brady of the Middle District of Louisiana stated that

Livingston Downs Racing Ass'n, Inc. v. Jefferson Downs Corp., 259 F.Supp.2d 471, 475 (M.D.La.2002) (internal citations omitted).

Turning to the standard applicable to a Rule 59(e) motion, a district court has considerable discretion to grant or deny a Rule 59(e) motion for reconsideration or to alter or amend a judgment. Edward H. Bohlin Co. v. Banning Co., 6 F.3d 350, 353 (5th Cir.1993). Notably, however, reconsideration "is an extraordinary remedy that should be used sparingly." Templet v. HydroChem Inc., 367 F.3d 473, 479 (5th Cir.2004) (citations omitted). It "serve[s] the narrow purpose of allowing a party to correct manifest errors of law or fact or to present newly discovered evidence." Id. Courts have granted Rule 59(e) motions for several reasons, including: "(1) the judgment is based upon a manifest error of fact or law; (2) newly discovered or previously unavailable evidence exists; (3) manifest injustice would otherwise result; (4) there has been serious misconduct by counsel; and (5) an intervening change in controlling law alters the appropriate outcome." Livingston Downs, 259 F.Supp.2d at 475-76 (citing cases). Indeed, Rule 59(e) motions are "not the proper vehicle for rehashing evidence, legal theories, or arguments that could have been offered or raised before the entry of judgment." Templet, 367 F.3d at 478-79.

The applicable standard for a Rule 60(b) motion is even stricter than that used in a Rule 59(e) motion. In order to succeed on a Rule 60(b) motion, the movant must show:

Rule 60(b) is used to "correct obvious errors or injustices." Fackelman v. Bell, 564 F.2d 734, 736 (5th Cir.1977). A party requesting relief under Rule 60(b) must show "unusual or unique circumstances" in order to prevail. Id.; Pryor v. U.S. Postal Service, 769 F.2d 281, 286 (5th Cir.1985).

LAW AND ANALYSIS

I. The Redhibition Claim under Article 2520 and Prescription

BASF first requests reconsideration of the court's decision regarding the prescription of the Hospital's breach of warranty against redhibitory defects claim under La. Civ.Code art. 2520 — as noted above, the court previously denied summary judgment on BASF's argument that the Hospital's redhibition claim had prescribed. BASF asserts that the court found that there were unresolved fact issues that warranted denial of BASF's prescription argument, but that this conflicted with other sections of the opinion, which seemed to affirmatively state that the redhibition claim had not prescribed. Essentially, BASF requests that the court amend its opinion to reflect that the issue of prescription on the redhibition claim should be preserved for the jury. BASF also argues that the court could not issue a ruling finding that the redhibition claim had not prescribed, because the Hospital had not affirmatively asked for such a ruling in its own Motion for Summary Judgment.

The Hospital counters by noting that there were no genuine disputes of material fact on the sequence of events leading up to the Hospital filing its lawsuit, and that the court thus properly found, as a matter of law and discerning the "legal effect" of the uncontested sequence of events, that the redhibition claim had not prescribed. The Hospital further notes that because, in its own Partial Motion for Summary Judgment, it requested a judgment declaring that the Hospital "may seek relief from BASF for the defective EIFS under ... implied warranties including the warranty against redhibitory defects (redhibition)," this indicates that the Hospital was requesting a ruling that the redhibition claim had not prescribed.

The court finds that BASF's request for clarification well-founded. Construing the evidence in the light most favorable to the Hospital, a genuine factual dispute remains as to whether the various offers to "pick and clean" continued to pause the prescriptive period; this is because a factual question remains as to whether it was reasonable for the Hospital to believe that remediation would continue after the correspondence exchanged between the parties in mid-2008. As expressed in the original opinion, the "`last date of repairs' rule must be tempered by another rule from Louisiana jurisprudence that `interruption of prescription will occur when there has been verbal or written communication which would reasonably lead a buyer to believe that the defects complained of would be remedied.'" Mem. Ruling [Doc. 62], at 40. Indeed, while the evidence shows there appeared to be a stalemate between the parties on the pick and clean issue in May 2008, a BASF representative nonetheless sent a letter again offering to pick and clean two of the Hospital buildings in June 2008, to which the Hospital responded with a letter agreeing to a "sample" pick and clean in August 2008. While there was a lapse in time between this final letter and the Hospital filing suit in April 2010, the Hospital presented evidence that such lag times were expected, based on prior interactions between the parties.

Thus, the court's original decision to deny summary judgment based on prescription was correct. To the extent the court's original opinion may be construed as having made affirmative statements that the redhibition claim certainly had not prescribed, however, these conclusions were premature and are thus stricken from the original opinion. A jury must be presented with witnesses and evidence from both sides, and assess for themselves when the remediation window closed and whether it was reasonable (based on the sequence of events and the working relationship BASF had with the Hospital) for the Hospital to believe that remediation would continue, thus pausing the prescriptive period. Cf. Moore v. A.G. Edwards & Sons, Inc., 631 F.Supp. 138 (E.D.La.1986) (denying summary judgment on a defendant's prescription argument because fact issues remained on whether a plaintiff knew or should have known of fraud, thus triggering the prescriptive period). Accordingly, to the extent that BASF requests clarification and amendment of the prior Memorandum Ruling on this issue,

IT IS ORDERED that Section II(B)(2) of the previous Memorandum Ruling [Doc. 62] is AMENDED to reflect that, while denial of BASF's summary judgment prescription argument on the redhibition claim was appropriate, any affirmative statements made by the court that the redhibition claim had definitely not prescribed must be STRICKEN.

II. Article 2524 Claim

Relying on its argument that the court found that the redhibition claim should be preserved for the jury, BASF also argues that the court should amend its ruling to reflect that it denied BASF's summary judgment motion on the validity of the Hospital's article 2524 claim in part because of fact issues remaining with the redhibition prescription issue. As noted above, the court relied on the Western District of Louisiana Justiss case as persuasive in guiding its inquiry as to whether a redhibition action and article 2524 action are mutually exclusive. This court agreed with the Justiss court's decision that the Louisiana Third Circuit case, Cunard Line Limited Co. v. Datrex, Inc., 05-1171 (La. App. 3 Cir. 4/5/06); 926 So.2d 109, which has been argued as standing for the proposition that an article 2520 claim is mutually exclusive from an article 2524 claim, was contrary to the conclusions reached by the "overwhelming majority of Louisiana appellate courts." Justiss, 2011 WL 539135 at *5. The Justiss court distinguished itself from Cunard in part by explaining that the Cunard court was faced with two different prescriptive periods — in Cunard, the oneyear redhibition period had clearly passed, whereas the ten-year article 2524 period had not. Id. In contrast, in Justiss, the court had earlier found that neither of the prescriptive periods had passed. Id. at *6. Thus, the Justiss plaintiffs were free to claim relief under both theories of recovery. Id. ("Louisiana law has long held that, absent conflicting prescriptive periods, a plaintiff may assert claims under both theories and is not required to plead a single theory of his case.") (citation omitted).

Upon careful consideration of the case law, it seems that the proper issue herein is not whether a warranty of redhibition claim can coexist in a suit with a warranty of fitness claim, but rather whether a warranty of fitness claim exists here at all. In this case, as already stated, the court cannot definitively declare whether the redhibition claim has prescribed or not, as unresolved issues of fact remain. As for the article 2524 claim: as noted by the Cunard court, article 2524 was added to the Louisiana Civil Code by La. Acts No. 841, § 1, effective January 1, 1995. Cunard, 926 So.2d at 113. Revision Comment (a) to article 2524 provides, in full:

The Revision Comments indicate that the previous caselaw erroneously confused a breach of warranty that the thing is fit for ordinary use with a breach of warranty against redhibitory defects. As the Cunard court discovered, it is not always a simple matter to distinguish a redhibition claim from a fitness claim.

Further, the Cunard court provides additional persuasive justifications for differentiating between a redhibition action and an article 2524 action, which bear repeating here:

Cunard, 926 So.2d at 113.

Applying this reasoning to its facts, the Cunard court found that a buyer's claim that a seller had sold it lighting systems which "shorted out" was "based on the allegedly defective nature of [the lighting] systems," and not instead based on the theory that the lighting systems were not fit for their ordinary use as a lighting system for the buyer's cruise ship. Id. at 113-14. While, of course, the defective lighting systems were no longer useful for their ordinary purpose — lighting the buyer's cruise ship — the reason arose from the redhibitory defect itself. See id. Accordingly, the Cunard court found the buyer-plaintiff's claims for relief arose from article 2520, not article 2524, thus meaning that the plaintiff was relegated to the comparatively shorter one-year prescriptive period for article 2520 claims. However, that conclusion is not to say that the article 2520 claims are necessarily mutually exclusive from article 2524 claims; it is only to say that they are "separate and distinct" causes of action which may be present in an action either collectively or individually. The crucial consideration is what type of issue a buyer has with a product in determining whether the warranty of redhibition or the warranty of fitness applies.

It is possible to imagine, for instance, a situation in which a seller knew of a buyer's intended use of a product, and a product which was unfit for that use and also contained a redhibitory defect was sold to a purchaser. Allowing a plaintiff in such a situation to bring an action under both theories of recovery would not seem to run afoul of Cunard.

The Cunard court stated that the "issue before [it was] whether La. Civ.Code art. 2524 is intended to encompass the warranty against redhibitory defects so as to provide an additional cause of action for defective products." Cunard, 926 So.2d at 113 (emphasis added). Thus, the question in Cunard was whether these actions were separate and distinct, as opposed to overlapping, not whether they were necessarily mutually exclusive.

With these principles in mind, the undersigned returns to the language of articles 2520 and 2524. Under article 2520, a redhibitory defect in a product is defined as something that "renders the thing useless, or its use so inconvenient that it must be presumed that a buyer would not have bought the thing had he known of the defect" or else "without rendering the thing totally useless, it diminishes its usefulness or its value so that it must be presumed that a buyer would still have bought it but for a lesser price." La. Civ.Code art. 2520. Thus, to use a simple example, suppose a buyer purchases a new vehicle from a car dealership, and several days later, a defect in the car transmission causes the car to shift erratically. In such a situation, the Louisiana Supreme Court has found that this faulty transmission issue would constitute a redhibitory defect under article 2520. See Prince, 281 So.2d at 115. Under article 2524, in contrast, a product is not fit for ordinary use "[w]hen the seller has reason to know the particular use the buyer intends for the thing, or the buyer's particular purpose for buying the thing, and that the buyer is relying on the seller's skill or judgment in selecting it." La. Civ.Code art. 2524. Thus, to use an alternative simplified example, suppose a buyer tells a seller that he requires a vehicle with enough towing capacity to tow a large-sized trailer. The seller proclaims that he has just the vehicle for the task, but, when the buyer actually hitches the trailer to his newly-purchased Mazda Miata, he is woefully disappointed to discover that, try as it might, the Miata cannot pull such a heavy load. While the Miata contains no hidden redhibitory defects, it is certainly unfit for the particular use the buyer intended it for, thus constituting a breach of warranty of fitness for ordinary use under article 2524 on the seller's part. Further, if the Miata then was found to suffer from a faulty transmission, the court can think of no compelling reason why the purchaser would not be able to bring an action under both articles 2520 and 2524. Such a conclusion would also be consistent with the Justiss court's holding that would allow both claims to co-exist in the same case, rejecting any alternative conclusion as an improper "interpretation of Cunard." Justiss, 2011 WL 539135 at *5. Nevertheless, such a determination is unnecessary to the adjudication of this case, as the court finds, after a thorough reexamination of the facts, that an article 2524 claim is not the appropriate vehicle for the plaintiff's recovery herein.

Applying these definitions to the facts at bar, while the inquiry is closer than the example above, the undersigned finds that the Hospital's claims sound in breach of warranty against redhibitory defects under article 2520 only, and not breach of warranty of fitness for ordinary use under article 2524. The Hospital's allegations center around the fact that, while they bought an EIFS that technically served its ordinary use as an exterior wall cladding system, the hidden redhibitory defect in the EIFS (iron pyrite particles) rendered the EIFS so "useless" or else "diminished in value" that the Hospital would not have bought it if it had known the EIFS would soon become spotted with rust. This is further supported by the court's uncontested earlier finding that the iron pyrite particles were a hidden redhibitory defect.11 In sum, because the court finds that the Hospital's claim sounds in redhibition rather than fitness, the Hospital does not have an actionable article 2524 claim. Accordingly,

IT IS ORDERED that the court's affirmative finding that the Hospital herein may assert an article 2524 claim in addition to its redhibition claim is STRICKEN from the original opinion, as the plaintiff may only submit a claim under article 2520 under a theory of a breach of the warranty against redhibitory defects.12

III. Waivers and Limitations of Implied Warranties in the Limited Warranty

The court will next address BASF's argument that the court erroneously found that the waivers and limitations of implied warranties in the Limited Warranty were unenforceable, thus granting the portion of the Hospital's summary judgment motion on this issue. In finding that the waivers were unenforceable, the court's inquiry turned on whether BASF brought the waivers and limitations to Michael Pomarico's (the Hospital architect) attention and explained them (the third prong of the three-part Prince test). The court found that while there was some evidence that the "submittals" contained some of the limitations and waivers of warranties, these limitations and waivers differed from the ultimate Limited Warranty that issued. Like with the redhibition prescription argument, BASF argues that by making an affirmative finding that the waivers and limitations were not brought to Pomarico's attention, which would thus make the Limited Warranty unenforceable, the court improperly took this factual dispute away from the jury and in so doing made a factual determination that was inappropriate in a motion for summary judgment.

The Hospital counters that the court, construing the uncontested submittals evidence, properly found that it was unnecessary for a jury to determine Pomarico's possible knowledge, in light of the lack of evidence on whether BASF brought the waivers and limitations to either Pomarico's attention or else another Hospital representative's attention. The Hospital further argues that BASF bore the burden of proof on proving the validity of waivers and remedy limitations, and that the court properly found that BASF could not satisfy this burden.

The court finds BASF's arguments wellfounded. It was premature for the court to affirmatively find that the waivers and remedies were definitively unenforceable and grant summary judgment in favor of the Hospital. Factual disputes remain on this issue — a jury must assess for themselves, by analyzing the evidence contained in the submittals and the live testimony of Pomarico and the various other Hospital and BASF parties who participated in the facility construction process, whether and to what extent the Hospital knew that remedies would be limited and warranties would be waived as they were in the final Limited Warranty. Indeed, as pointed out by BASF, the primary opinion that the court relied on to find that the waivers and limitations were unenforceable, Gulf South Mach., Inc. v. Kearney & Trecker Corp., 756 F.2d 377 (5th Cir.1985) was the result of a jury trial, not a summary judgment motion.

The court notes that, as other portions of its decision on the Hospital's motion relied on the reasoning and findings from the section that discusses the Prince test (Section I(A)(2) titled "Meeting of the minds" on waivers and limitations, and Section I(B), titled "Construing Ambiguity in the Warranty"), these portions of the Hospital's motion similarly should have been denied.

Additionally, the court addresses the remaining section of its original opinion challenged by BASF, Section I(A)(3) ("Waiver of warranty limitations through Finestone's conduct in agreeing to remediate"). The court found that BASF's actions, in offering to remediate again and again, meant that BASF had waived its right to assert that the Hospital was relegated to a refund of the purchase price or replacement of the product. The court's analysis turned in large part on the reasoning found in a Louisiana Second Circuit case, Sabbath v. Martin, 2009 WL 3449096 (La.App. 2 Cir. 10/28/09), In Sabbath, the Louisiana Second Circuit affirmed a trial court's ruling that a car dealer's repeated offers to fix a faulty car constituted a waiver on the dealer's part of the waiver of warranty clause found in the car's bill of sale. Importantly, the trial court entered this judgment after a "trial on the merits," after assessing evidence on "two disputed facts ... (i) [the plaintiff's] understanding of any waiver of warranty and (ii) [the plaintiff's] consent to allow the final repairs to the vehicle to be performed at her costs." The court finds that it was premature to affirmatively find BASF, by offering to remediate on several occasions, definitively waived its right to assert the waivers of warranties and limitations of remedies found within the Limited Warranty. Accordingly,

IT IS ORDERED that Section 1(A)(1)(b) of the Memorandum Ruling [Doc. 62] is AMENDED to reflect that factual disputes remain as to whether BASF properly brought the warranty waivers and limitations of remedies in the Limited Warranty to the Hospital's attention, and thus the court's affirmative finding that the Limited Warranty waivers and limitations are unenforceable is STRICKEN;

IT IS FURTHER ORDERED that Section I(A)(2) is AMENDED to reflect that factual disputes remain as to whether there was a "meeting of the minds" between BASF and the Hospital on the warranty waivers and limitations of remedies contained in the Limited Warranty. Thus, the court's affirmative finding that there was no meeting of the minds is STRICEN;

IT IS FURTHER ORDERED that Section I(A)(3) is AMENDED to reflect that factual disputes remain on whether BASF waived its Limited Warranty by continually offering to remediate instead of offering the limited remedies contained in the Limited Warranty. Thus, the court's affirmative finding that BASF had waived the Limited Warranty limitations and waivers is STRICKEN;

IT IS FURTHER ORDERED that Section I(B) is AMENDED to reflect that, in light of the fact that a factual dispute remains on whether the Limited Warranty is enforceable, it is premature to discern whether and to what extent ambiguities in the Limited Warranty should be construed in favor of the Hospital.

IV. The Judgment

Finally, the court turns to BASF's request for clarifications within the Judgment. In the original Judgment, the court granted the Hospital's motion in its entirety, and denied BASF's motion in its entirety. In light of this opinion, the court reaffirms its decision to deny summary judgment on BASF's prescription argument, but reverses its decision to deny summary judgment on BASF's article 2524 argument. Accordingly,

IT IS ORDERED that the Judgment [Doc. 60] is AMENDED to reflect that BASF's Motion for Summary Judgment [Doc. 41] is GRANTED to the limited extent that the court agrees, as a matter of law, that the Hospital does not have a viable article 2524 claim, but otherwise remains DENIED as to all other claims raised in the motion.

As for the Hospital's Partial Motion for Summary Judgment, as noted supra, the court agrees that factual disputes remain as to whether the Hospital had notice of the waivers of warranties and limitations of remedies which appeared in the final Limited Warranty. The court also finds that it was premature to affirmatively find that BASF had waived its right to assert the limited remedies and waivers of warranties found in the Limited Warranty. Accordingly,

IT IS ORDERED that the Judgment [Doc. 60] is AMENDED to reflect that the Hospital's Partial Motion for Summary Judgment [Doc. 40] is DENIED as premature as to all claims.